cor2ed
engage checkpoint medical linkedin twitter
bg

Treating mCRPC patients who have progressed on AR-directed therapy

Treating mCRPC patients who have progressed on AR-directed therapy

Dr. Fabio Schutz

Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Portrait of Fabio Schutz
Dr. Fabio Schutz

Medical Oncologist

Beneficencia Portuguesa de São Paulo

Brazil

preview next

time Expert View | open 5 min

download resources

I agree that this educational programme:

Was valuable to me:

1/3

Other programmes of interest

Other programmes developed by Dr. Fabio Schutz